GLAXOSMITHKLINE’S new chief executive, who has already made her mark with plans to divest some nutritional products, will turn next week to the main business of focusing the company’s pipeline of new drugs.
Despite her non-pharmaceutical background in consumer brands, Emma Walmsley sees improving drug research productivity as her top priority, and she wants Britain’s biggest drugmaker to have fewer but potentially more lucrative new medicine launches in future.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!